New inhaled drug KIT2014 tested for COPD – early trial begins

NCT ID NCT07668518

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an inhaled drug called KIT2014 in 36 adults with moderate to severe COPD. Participants will receive either the drug or a placebo daily for 7 days. The main goal is to check safety and how the body handles the drug, with a first look at whether it might help breathing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

KIT2014 (inhaled drug)

What this could lead to

If it works, this could point toward a new inhaled treatment to help control COPD symptoms and improve lung function.

What could go wrong

This is an early-phase trial with only 36 people and 7 days of treatment. It is designed mainly to check safety, not to prove effectiveness. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Novatrials

    Charlestown, New South Wales, 2291, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••